213 related articles for article (PubMed ID: 27174055)
1. G9a - An Appealing Antineoplastic Target.
Chen WL; Sun HP; Li DD; Wang ZH; You QD; Guo XK
Curr Cancer Drug Targets; 2017; 17(6):555-568. PubMed ID: 27174055
[TBL] [Abstract][Full Text] [Related]
2. Insights for the design of protein lysine methyltransferase G9a inhibitors.
Charles MRC; Dhayalan A; Hsieh HP; Coumar MS
Future Med Chem; 2019 May; 11(9):993-1014. PubMed ID: 31141392
[TBL] [Abstract][Full Text] [Related]
3. Recent progress in histone methyltransferase (G9a) inhibitors as anticancer agents.
Cao H; Li L; Yang D; Zeng L; Yewei X; Yu B; Liao G; Chen J
Eur J Med Chem; 2019 Oct; 179():537-546. PubMed ID: 31276898
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and biological evaluation of benzimidazole derivatives as the G9a Histone Methyltransferase inhibitors that induce autophagy and apoptosis of breast cancer cells.
Zhang J; Yao D; Jiang Y; Huang J; Yang S; Wang J
Bioorg Chem; 2017 Jun; 72():168-181. PubMed ID: 28460359
[TBL] [Abstract][Full Text] [Related]
5. Discovery of an in vivo chemical probe of the lysine methyltransferases G9a and GLP.
Liu F; Barsyte-Lovejoy D; Li F; Xiong Y; Korboukh V; Huang XP; Allali-Hassani A; Janzen WP; Roth BL; Frye SV; Arrowsmith CH; Brown PJ; Vedadi M; Jin J
J Med Chem; 2013 Nov; 56(21):8931-42. PubMed ID: 24102134
[TBL] [Abstract][Full Text] [Related]
6. Properly substituted analogues of BIX-01294 lose inhibition of G9a histone methyltransferase and gain selective anti-DNA methyltransferase 3A activity.
Rotili D; Tarantino D; Marrocco B; Gros C; Masson V; Poughon V; Ausseil F; Chang Y; Labella D; Cosconati S; Di Maro S; Novellino E; Schnekenburger M; Grandjenette C; Bouvy C; Diederich M; Cheng X; Arimondo PB; Mai A
PLoS One; 2014; 9(5):e96941. PubMed ID: 24810902
[TBL] [Abstract][Full Text] [Related]
7. Protein lysine methyltransferase G9a inhibitors: design, synthesis, and structure activity relationships of 2,4-diamino-7-aminoalkoxy-quinazolines.
Liu F; Chen X; Allali-Hassani A; Quinn AM; Wigle TJ; Wasney GA; Dong A; Senisterra G; Chau I; Siarheyeva A; Norris JL; Kireev DB; Jadhav A; Herold JM; Janzen WP; Arrowsmith CH; Frye SV; Brown PJ; Simeonov A; Vedadi M; Jin J
J Med Chem; 2010 Aug; 53(15):5844-57. PubMed ID: 20614940
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
Lenstra DC; Al Temimi AHK; Mecinović J
Bioorg Med Chem Lett; 2018 Apr; 28(7):1234-1238. PubMed ID: 29519735
[TBL] [Abstract][Full Text] [Related]
9. Involvement of histone H3 lysine 9 (H3K9) methyltransferase G9a in the maintenance of HIV-1 latency and its reactivation by BIX01294.
Imai K; Togami H; Okamoto T
J Biol Chem; 2010 May; 285(22):16538-45. PubMed ID: 20335163
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of H3K9 histone methyltransferase G9a attenuates renal fibrosis and retains klotho expression.
Irifuku T; Doi S; Sasaki K; Doi T; Nakashima A; Ueno T; Yamada K; Arihiro K; Kohno N; Masaki T
Kidney Int; 2016 Jan; 89(1):147-57. PubMed ID: 26444031
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294.
Chang Y; Zhang X; Horton JR; Upadhyay AK; Spannhoff A; Liu J; Snyder JP; Bedford MT; Cheng X
Nat Struct Mol Biol; 2009 Mar; 16(3):312-7. PubMed ID: 19219047
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Potent and Selective Inhibitors for G9a-Like Protein (GLP) Lysine Methyltransferase.
Xiong Y; Li F; Babault N; Dong A; Zeng H; Wu H; Chen X; Arrowsmith CH; Brown PJ; Liu J; Vedadi M; Jin J
J Med Chem; 2017 Mar; 60(5):1876-1891. PubMed ID: 28135087
[TBL] [Abstract][Full Text] [Related]
13. Histone methyltransferase G9a and H3K9 dimethylation inhibit the self-renewal of glioma cancer stem cells.
Tao H; Li H; Su Y; Feng D; Wang X; Zhang C; Ma H; Hu Q
Mol Cell Biochem; 2014 Sep; 394(1-2):23-30. PubMed ID: 24833465
[TBL] [Abstract][Full Text] [Related]
14. G9a/GLP histone lysine dimethyltransferase complex activity in the hippocampus and the entorhinal cortex is required for gene activation and silencing during memory consolidation.
Gupta-Agarwal S; Franklin AV; Deramus T; Wheelock M; Davis RL; McMahon LL; Lubin FD
J Neurosci; 2012 Apr; 32(16):5440-53. PubMed ID: 22514307
[TBL] [Abstract][Full Text] [Related]
15. Histone lysine methyltransferase G9a is a novel epigenetic target for the treatment of hepatocellular carcinoma.
Yokoyama M; Chiba T; Zen Y; Oshima M; Kusakabe Y; Noguchi Y; Yuki K; Koide S; Tara S; Saraya A; Aoyama K; Mimura N; Miyagi S; Inoue M; Wakamatsu T; Saito T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Otsuka M; Miyazaki M; Yokosuka O; Iwama A
Oncotarget; 2017 Mar; 8(13):21315-21326. PubMed ID: 28423509
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel quinoline inhibitor for EHMT2/G9a through virtual screening.
Charles MRC; Mahesh A; Lin SY; Hsieh HP; Dhayalan A; Coumar MS
Biochimie; 2020 Jan; 168():220-230. PubMed ID: 31756401
[TBL] [Abstract][Full Text] [Related]
17. Targeting EHMT2/ G9a for cancer therapy: Progress and perspective.
Jan S; Dar MI; Wani R; Sandey J; Mushtaq I; Lateef S; Syed SH
Eur J Pharmacol; 2021 Feb; 893():173827. PubMed ID: 33347828
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of H3K9 methyltransferase G9a induces autophagy and apoptosis in oral squamous cell carcinoma.
Ren A; Qiu Y; Cui H; Fu G
Biochem Biophys Res Commun; 2015 Mar; 459(1):10-7. PubMed ID: 25634693
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral in Vivo Efficacy.
Rabal O; San José-Enériz E; Agirre X; Sánchez-Arias JA; Vilas-Zornoza A; Ugarte A; de Miguel I; Miranda E; Garate L; Fraga M; Santamarina P; Fernandez Perez R; Ordoñez R; Sáez E; Roa S; García-Barchino MJ; Martínez-Climent JA; Liu Y; Wu W; Xu M; Prosper F; Oyarzabal J
J Med Chem; 2018 Aug; 61(15):6518-6545. PubMed ID: 29953809
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of H3K9 methyltransferase G9a ameliorates methylglyoxal-induced peritoneal fibrosis.
Maeda K; Doi S; Nakashima A; Nagai T; Irifuku T; Ueno T; Masaki T
PLoS One; 2017; 12(3):e0173706. PubMed ID: 28278257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
